Depósito Digital de Documentos de la UAB Encontrados 36 registros  1 - 10siguientefinal  ir al registro: La búsqueda tardó 0.01 segundos. 
1.
6 p, 754.7 KB Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial / Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ; André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ; Taieb, Julien (UMR-S 1147, INSERM) ; Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ; Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Hickish, Tamas (Royal Bournemouth Hospital and Bournemouth University. Department of Oncology) ; de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ; Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ; Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 - 10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317  
2.
16 p, 7.8 MB Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor / Martín-Antonio, B. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Suñe, G. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Najjar, A. (Department of Pediatrics-Research. University of Texas M. D. Anderson Cancer Center) ; Perez-Amill, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Antonaña-Vildosola, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Castella, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; León, S. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Velasco-De Andrés, M. (Immunoreceptors of the Innate and Adaptive System Group. IDIBAPS) ; Lozano, F. (Department of Biomedical Sciences. School of Medicine. University of Barcelona) ; Lozano, E. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Estanyol, J.M. (Proteomic Department. University of Barcelona) ; Munõz-Pinedo, Cristina (Institut d'Investigació Biomèdica de Bellvitge) ; Robinson, S.N. (Department of Stem Cell Transplantation and Cellular Therapy. University of Texas M. D. Anderson Cancer Center) ; Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Background: Natural killer (NK) cells are important anti-tumor cells of our innate immune system. Their anti-cancer activity is mediated through interaction of a wide array of activating and inhibitory receptors with their ligands on tumor cells. [...]
2019 - 10.1186/s40425-019-0739-1
Journal for immunotherapy of cancer, Vol. 7 Núm. 1 (16 2019) , p. 259  
3.
4 p, 972.8 KB Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma : implications for biomarker-driven clinical trials / Montal, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Andreu-Oller, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Bassaganyas, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteban-Fabró, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moran, Sebastian (Institut d'Investigació Biomèdica de Bellvitge) ; Montironi, C. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moeini, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Pinyol, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Peix, J. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cabellos, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Villanueva, A. (Liver Cancer Program. Division of Liver Diseases. Icahn School of Medicine at Mount Sinai) ; Sia, D. (Liver Cancer Program. Division of Liver Diseases. Icahn School of Medicine at Mount Sinai) ; Mazzaferro, V. (University of Milan and Gastrointestinal Surgery and Liver Transplantation Unit. Fondazione IRCCS. Istituto Nazionale dei Tumori) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Llovet, J.M. (Institució Catalana de Recerca i Estudis Avançats (ICREA)) ; Universitat Autònoma de Barcelona
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. [...]
2019 - 10.1038/s41416-019-0513-7
British Journal of Cancer, Vol. 121 Núm. 4 (13 2019) , p. 340-343  
4.
13 p, 5.4 MB Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity / Zanetti, SR (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Romecín, Paola Alejandra (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Vinyoles, Meritxell (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Juan, M. (Hospital Clínic i Provincial de Barcelona) ; Fuster, J.L. (Instituto Murciano de Investigación Biosanitaria) ; Cámos, M. (Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). Isciii) ; Querol, S. (Blood and Tissue Bank) ; Delgado, M. (Instituto de Parasitología y Biomedicina López-Neyra-CSIC) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Background Although adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells (CD19-CAR T-cells) achieves high rates of complete response in patients with B-cell acute lymphoblastic leukemia (B-ALL), relapse is common. [...]
2020 - 10.1136/jitc-2020-001419
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (31 2020) , p. e001419  
5.
11 p, 5.7 MB Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope / Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zanetti, SR (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Petazzi, Paolo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sánchez-Martínez, D. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Molina, Oscar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Baroni, Matteo Libero (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fuster, J.L. (Sección de Oncohematología Pediátrica. Hosp. Clin. Universitario Virgen de la Arrixaca and Instituto Murciano de Investigacion Biosanitaria) ; Ballerini, P. (Department of Pediatric Hemato-oncology. Armand-Trousseau Childrens Hospital) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Fernandez-Fuentes, N. (Universitat de Vic - Universitat Central de Catalunya) ; Engel, P. (Department of Biomedicine. School of Medicine. University of Barcelona) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. [...]
2020 - 10.1136/jitc-2020-000896
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (november 2020) , p. e000896  
6.
12 p, 2.0 MB 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo / Libero Baroni, Matteo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Sánchez Martínez, Diego (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Gutiérrez-Agüera, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Roca Ho, Heleia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Castellà, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Zanetti, SR (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Velasco-Hernández, Talia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Díaz de la Guardia, Rafael (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Castaño Cardoso, Julio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Anguita, E. (Hospital Clínico San Carlos (Madrid)) ; Vives, S. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ; Lapillone, H. (Centre de Recherce Saint-Antoine. Armand-Trousseau Childrens Hospital. Île-de-France) ; Bras, A.E. (Immunology Department. Erasmus Medical Center) ; van der Velden, V.H.J. (Immunology Department. Erasmus Medical Center) ; Junca, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Marin, P. (Hospital Clínic i Provincial de Barcelona) ; Bataller, A. (Hospital Clínic i Provincial de Barcelona) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Vick, B. (Helmholtz Center. Munich German Research Center for Environmental Health) ; Jeremias, I. (Pediatrics Department. Munich University Hospital Dr von Hauner Children's Hospital. Munchen) ; Lopez, A. (Human Immunology Department. Centre for Cancer Biology) ; Sorigue, Marc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bueno, Clara (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Menéndez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. [...]
2020 - 10.1136/jitc-2020-000845
Journal for immunotherapy of cancer, Vol. 8 Núm. 1 (january 2020)  
7.
6 p, 332.7 KB Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype / Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Tobeña, María (Institut d'Investigació Biomèdica Sant Pau) ; Fernández-Plana, Julen (Hospital Universitario Mutua Terrassa. Medical Oncology Department) ; Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Virgili, Anna C. (Institut d'Investigació Biomèdica Sant Pau) ; Cirera, Lluís (Hospital Universitario Mutua Terrassa. Medical Oncology Department) ; Barnadas, Agustí (Institut d'Investigació Biomèdica Sant Pau) ; Riera, Pau (Institut d'Investigació Biomèdica Sant Pau) ; Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ; Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ; Universitat Autònoma de Barcelona
Patients harbouring the UGT1A1 *28/*28 genotype are at risk of severe toxicity with the standard irinotecan dose. However, this dose is considerably lower than the dose that can be tolerated by UGT1A1 *1/*1 and *1/*28 patients. [...]
2018 - 10.1038/s41416-018-0348-7
British Journal of Cancer, Vol. 120 (december 2018) , p. 190-195  
8.
15 p, 1.5 MB Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells / Cordani, Marco (Universidad Autónoma de Madrid. Instituto de Investigaciones Biomédicas "Alberto Sols") ; Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Torrens-Mas, Margalida (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ; Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ; Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ; Nadal-Serrano, Mercedes (Vall d'Hebron Institut d'Oncologia) ; Coan, Michela (CRO National Cancer Institute Aviano. Division of Molecular Oncology, Department of Translational Research) ; Rossi, Davide (Institute of Oncology Research) ; Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ; Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ; Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Spizzo, Riccardo (CRO National Cancer Institute Aviano. Division of Molecular Oncology, Department of Translational Research) ; Roca, Pilar (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ; Oliver, Jordi (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ; Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ; Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ; Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 - 10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008  
9.
7 p, 1.3 MB Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer / Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ; Garcia-Carbonero, Rocio (Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain) ; Macarulla, Teresa (Vall d'Hebron Institut d'Oncologia) ; Pezet, Denis (Centre Hospitalier Universitaire) ; Deplanque, Gael (Hôpital Riviera-Chablais) ; Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ; Trojan, Jorg (Goethe University Medical Center) ; Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ; Kozloff, Mark (Ingalls Memorial Hospital) ; Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Smith, Claire (formerly of Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ; Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ; Blunt, Al (Advaxis, Inc) ; Benhadji, Karim A. (Eli Lilly and Company) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214  
10.
7 p, 549.5 KB Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma / Powles, Thomas (University of London. Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, Queen Mary) ; Motzer, Robert J. (Memorial Sloan Kettering Cancer Center) ; Escudier, Bernard (Gustave Roussy) ; Pal, Sumanta (City of Hope National Medical Center) ; Kollmannsberger, Christian (BCCA Vancouver Cancer Centre. British Columbia Cancer Agency) ; Pikiel, Joanna (Wojewodzkie Centrum Onkologii, 80-219 Gdańsk, Poland) ; Gurney, Howard (Macquarie University. Macquarie University and Westmead Hospital) ; Rha, Sun Young (Yonsei Cancer Center. Severance Hospital) ; Park, Se Hoon (Samsung Medical Center) ; Geertsen, Poul F. (Copenhagen University. Herlev and Gentofte Hospital, Herlev Hospital) ; Gross-Goupil, Marine (Groupe Hospitalier Saint André, 33000 Bordeaux, France) ; Grande, Enrique (Hospital Universitario Ramón y Cajal) ; Suarez, Cristina (Vall d'Hebron Institut d'Oncologia) ; Markby, David W. (Exelixis, Inc) ; Arroyo, Alan (Exelixis, Inc) ; Dean, Mark (Exelixis, Inc) ; Choueiri, Toni K. (Dana-Farber Cancer Institute) ; George, Daniel (Duke University Medical Center) ; Universitat Autònoma de Barcelona
In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) versus everolimus in patients with advanced renal cell carcinoma (RCC), after prior antiangiogenic therapy. [...]
2018 - 10.1038/s41416-018-0164-0
British Journal of Cancer, Vol. 119 (september 2018) , p. 663-669  

Depósito Digital de Documentos de la UAB : Encontrados 36 registros   1 - 10siguientefinal  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.